Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — RedEye Life Science Day, Stockholm 2019

20 slides from Herantis Pharma's conference presentation, Nov 19, 2019

  1. Slide 1: Toward clinical breakthroughs based on leading science

    Slide 1: Toward clinical breakthroughs based on leading science

    Toward clinical breakthroughs based on leading science RedEye Life Science Day, Stockholm 19 Nov 2019 Pekka Simula, CEO 1 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer • This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc (‘Company’). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in

  3. Slide 3: Breaking the boundaries of standard therapeutic approaches

    Slide 3: Breaking the boundaries of standard therapeutic approaches

    Breaking the boundaries of standard therapeutic approaches 3 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  4. Slide 4: Herantis' target indications

    Slide 4: Herantis' target indications

    Herantis’ target indications Parkinson’s disease (PD) Secondary lymphedema PD is an incurable brain disease whose first symptoms include tremors, muscle stiffness → Symptoms grow worse with disease progression → Known drugs only treat motor symptoms, only for a while Lymphedema (LE) is chronic, prog

  5. Slide 5: Parkinson's and lymphedema facts

    Slide 5: Parkinson's and lymphedema facts

    Parkinson’s facts: Lymphedema facts: • Second most common • 140 million LE patients neurodegenerative disease: • 2 million breast cancer 7-10 million patients diagnosis annually • Estimated annual financial burden of PD is $50 billion → 30% of patients who undergo mastectomy will develop • Progressi

  6. Slide 6: By developing disease-modifying treatments, we fight human suffering and societal costs

    Slide 6: By developing disease-modifying treatments, we fight human suffering and societal costs

    By developing disease-modifying treatments, we fight both human suffering and societal costs 11/18/19 6 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  7. Slide 7: PD: Our drug candidate CDNF promotes neuronal survival and recovery

    Slide 7: PD: Our drug candidate CDNF promotes neuronal survival and recovery

    PD: Our drug candidate CDNF promotes neuronal survival and recovery through multiple relevant mechanisms • CDNF helps stressed or injured neurons survive and recover • Mechanisms relevant to PD • Promising data in several neurological diseases 7 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All

  8. Slide 8: CDNF doubled the number of neurons in a PD model

    Slide 8: CDNF doubled the number of neurons in a PD model

    CDNF doubled the number of neurons in a PD model* Vehicle 150 µg CDNF 80% loss of dopaminergic neurons Doubled the number of dopaminergic neurons • Disease model: MPTP lesion model in aged Rhesus monkey • Three monthly CDNF doses doubled the number of DA neurons • Significant improvement in gross mo

  9. Slide 9: CDNF may change how patients live with PD

    Slide 9: CDNF may change how patients live with PD

    CDNF may change how patients live with PD Currently in Phase 1-2 clinical study funded by EU: “Leading science, greatest potential to advance clinical practice” Ø Study fully recruited: 17 patients randomized in CDNF vs. placebo groups Ø Topline results expected in Q1/2020 Ø First-in-human study in

  10. Slide 10: Next generation: xCDNF

    Slide 10: Next generation: xCDNF

    Next generation: xCDNF • Common challenge in brain diseases is drug delivery in the brains à CDNF is dosed directly in brains using medical device • Next step: we have shown that certain CDNF fragments: 1. Retain its biological activity (comparable efficacy in PD models) 2. Penetrate the BBB à much

  11. Slide 11: Lymfactin gene therapy for curing secondary lymphedema

    Slide 11: Lymfactin gene therapy for curing secondary lymphedema

    Lymfactin® gene therapy for curing secondary lymphedema 11 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  12. Slide 12: Lymfactin: VEGF-C gene therapy to reconstitute the lymphatic system

    Slide 12: Lymfactin: VEGF-C gene therapy to reconstitute the lymphatic system

    Lymfactin®: VEGF-C gene therapy to reconstitute the lymphatic system 1. A single Lymfactin® injection results in local VEGF-C expression for about 2 weeks 2. VEGF-C is the natural human protein that promotes the growth of lymphatic capillaries 3. Lymphatic capillaries mature into functional lymphati

  13. Slide 13: Lymfactin development

    Slide 13: Lymfactin development

    Lymfactin® development • Actively recruiting patients with breast cancer associated LE (BCAL) → Adjunct to lymph node transplantation surgery, which attempts to relieve symptoms → Study centers: 5 university hospitals in Sweden and Finland • Safety established in Phase 1 study with same approach → P

  14. Slide 14: Lymphedema: Market and awareness

    Slide 14: Lymphedema: Market and awareness

    Lymphedema: Market and awareness • 140 million LE patients worldwide • €600M market for Lymfactin® as an adjunct therapy in BCAL* → Significant potential in other lymphedemas • Lymphedema awareness increases → Herantis is a partner of LE&RN, international patient advocacy group → Hollywood superstar

  15. Slide 15: Summary and Public Offering in Sweden

    Slide 15: Summary and Public Offering in Sweden

    Summary and Public Offering in Sweden 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  16. Slide 16: CDNF and Lymfactin are in placebo-controlled studies targeting unmet clinical needs

    Slide 16: CDNF and Lymfactin are in placebo-controlled studies targeting unmet clinical needs

    Based on leading science, CDNF and Lymfactin® are in placebo-controlled studies targeting unmet clinical needs COMPANY’S ESTIMATE ON MARKET POTENTIAL EUR 600m EUR 1.6bn Not provided 16 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

  17. Slide 17: Public company in Finland since 2014: Now dual-listing in Sweden

    Slide 17: Public company in Finland since 2014: Now dual-listing in Sweden

    Public company in Finland since 2014: HRTIS Now dual-listing in Sweden First North listed • Herantis announced on 11 Nov 2019: → Public offering in Sweden and Denmark, and private placement: max 618,018 shares to be issued at 71 SEK (~€6.65) per share → Application to Nasdaq to have Herantis’ shares

  18. Slide 18: Selected financials as reported 1H/2019

    Slide 18: Selected financials as reported 1H/2019

    Selected financials as reported 1H/2019 H1/2019 H1/2018 Cash end of period 5.6 MEUR 4.0 MEUR Cash flow from operations -2.7 MEUR -1.8 MEUR Personnel 9 9 • Market cap approximately 450 MSEK (Nov 18th, 2019) • Last funding round in 3/2019 → Cornerstone investor: Swedbank Robur’s healthcare fund Medica

  19. Slide 19: Meet us during subscription period in Nov!

    Slide 19: Meet us during subscription period in Nov!

    Meet us during subscription period in Nov! • Scheduled events at United Bankers, Cardellgatan 1, Stockholm (5 min from Stureplan) → Please register by e-mail: event@unitedbankers.com Date Time Notes Thu, Nov 21st 12:00 – 13:00 Light lunch served Thu, Nov 21st 15:00 – 16:00 Coffee served Fri, Nov 22n

  20. Slide 20: Thank you

    Slide 20: Thank you

    Thank you E-mail: pekka.simula@herantis.com Twitter: @HerantisPharma Blog: http://herantis.com/blog/ 20 11/18/19 www.herantis.com © 2014-2019 HERANTIS PHARMA Plc. All rights reserved.

Source: Internet Archive copy of herantis.com

More decks from Herantis Pharma PLC

All 33 Herantis Pharma decks